Business Standard

AstraZeneca's drug gets US FDA nod to treat lung disease patients

The drug Breztri Aerosphere is being approved as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD), the third leading cause of death globally

medicine, drugs, pharma
Premium

The approval for AstraZeneca comes at a time when the British drugmaker is seeking to catch up with the runaway success of rival Glaxosmithkline's Trelegy Ellipta drug

Reuters
The US Food and Drug Administration approved AstraZeneca's drug to treat patients with a form of lung disease, the British drugmaker said on Friday.

The drug Breztri Aerosphere is being approved as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD), the third leading cause of death globally, AstraZeneca said.

Known as "smoker's lung", COPD is a progressively worsening and potentially deadly condition that affects more than 380 million people worldwide, primarily caused by smoking, but also by occupational hazards such as air pollution or chemical fumes.

The approval for AstraZeneca comes at a time when the British

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 28 2020 | 9:06 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com